semaglutide 1.75 mg GLP-1 Drug Fails to Quell Alzheimer's in Novo Nordisk Trials such as high blood pressure Navigating the New Frontier: FDA's

Affected individuals are typically characterised by lipoatrophic diabetes, insulin resistance and hepatic steatosis ( Agonists of the glucagon-like peptide-1 receptor (GLP-1R) deliver significant beneficial effects both in treating type 2 diabetes and obesity ( Reports of the effects of GLP-1R agonists in individuals with inherited lipodystrophies are currently limited to only 3 case studies, and these examine FPLD but not CGL patients ( Here we used a well validated Bscl2 -null (seipin knockout) mouse model of CGL type 2 (CGL2) to examine the effectiveness of a GLP-1R agonist, in treating lipoatrophic diabetes, hepatic steatosis and hyperphagia in CGL to inform the adoption of this class of drugs for individuals with lipodystrophy

GHRP-2 structure and broader activity: GHRP-2 is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) with high GHSR-1a binding affinity

GLP-1-RA such as liraglutide [4], semaglutide [5], and the dual agonist tirzepatide [6], activating both the GLP1- and the gastric-inhibitory polypeptide receptor (GIP-R), have been shown to significantly reduce body weight, making them a promising therapeutic option for the treatment of obesity

Yang XH, Ren X, Guo C, Hu J, Fu